Clinical trial
Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian…
NCT00112957 · Ludwig Institute for Cancer Research, Other · Completed
Key facts
| NCT number | NCT00112957 |
|---|---|
| Title | Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer |
| Official title | Phase II Study of Recombinant Vaccinia-NY-ESO-1 (rV-NY-ESO-1) and Recombinant Fowlpox-NY-ESO-1 (rF-NY-ESO-1) in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen |
| Lead sponsor | Ludwig Institute for Cancer Research, Other |
| Collaborators | Roswell Park Cancer Institute |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer |
| Intervention type | Biological |
| Interventions | rV-NY-ESO-1 vaccine, rF-NY-ESO-1 vaccine |
| Enrollment | 23 |
| Start date | Dec 1, 2004 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Jun 3, 2005 |
| Last update posted | Oct 4, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: